The glucocorticoid dexamethasone is the standard of care in critically ill patients with COVID-19 to suppress the inap-propriately heightened inflammatory response (cytokine storm), but the Janus kinase inhibitor baricitinib combined with remdesivir has received emergency use authorization for the same indication
Conclusions: Our study suggests that the combination of baricitinib, dexamethasone, and remdesivir is effective and tolerable in hypoxic patients with COVID-19
Background: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19
All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control)
Append research in this systematic review and meta‐analysis were chosen as most likely attaining the coming criteria: follow the PICO framework (P, Populations—hospitalized coronavirus disease 2019 patients; I
2020 Dec 11:NEJMoa2031994
Patients were randomly assigned to receive baricitinib plus high-dose dexamethasone or high-dose dexamethasone monotherapy
On the other hand, baricitinib is not recommended outside clinical trials in Europe, considering the published national